Danny Rischin
Danny Rischin
Unknown affiliation
Verified email at petermac.org
Title
Cited by
Cited by
Year
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ...
Journal of clinical oncology 21 (12), 2237-2246, 2003
36882003
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ...
Journal of clinical oncology 20 (21), 4292-4302, 2002
9622002
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial
D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ...
Journal of clinical oncology 28 (27), 4142, 2010
7022010
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ...
Journal of Clinical Oncology 20 (1), 110-124, 2002
5982002
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02
LJ Peters, B O'Sullivan, J Giralt, TJ Fitzgerald, A Trotti, J Bernier, J Bourhis, ...
Journal of clinical oncology 28 (18), 2996-3001, 2010
5642010
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer …
D Rischin, RJ Hicks, R Fisher, D Binns, J Corry, S Porceddu, LJ Peters
Journal of Clinical Oncology 24 (13), 2098-2104, 2006
5052006
Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non–small-cell …
MP Mac Manus, RJ Hicks, JP Matthews, A McKenzie, D Rischin, ...
Journal of clinical oncology 21 (7), 1285-1292, 2003
4652003
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ...
New England Journal of Medicine 379 (4), 341-351, 2018
3602018
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck
JS Stewart, EE Cohen, L Licitra, CM Van Herpen, C Khorprasert, ...
J Clin Oncol 27 (11), 1864-1871, 2009
3482009
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
SN Holden, SG Eckhardt, R Basser, R De Boer, D Rischin, M Green, ...
Annals of Oncology 16 (8), 1391-1397, 2005
3212005
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of …
D Rischin, LJ Peters, B O’Sullivan, J Giralt, R Fisher, K Yuen, A Trotti, ...
Oncology, 2008
3102008
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel
JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, ...
Gynecologic oncology 63 (1), 89-93, 1996
2841996
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer
SV Porceddu, E Jarmolowski, RJ Hicks, R Ware, LA Weih, D Rischin, ...
Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2005
2702005
Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the …
D Rischin, L Peters, R Fisher, A Macann, J Denham, M Poulsen, ...
Journal of Clinical Oncology 23 (1), 79-87, 2005
2682005
F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high …
MP Mac Manus, RJ Hicks, DL Ball, V Kalff, JP Matthews, E Salminen, ...
Cancer 92 (4), 886-895, 2001
2642001
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
M Friedlander, KC Hancock, D Rischin, MJ Messing, CA Stringer, ...
Gynecologic oncology 119 (1), 32-37, 2010
2322010
Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
D Rischin, L Peters, R Hicks, P Hughes, R Fisher, R Hart, M Sexton, ...
Journal of Clinical Oncology 19 (2), 535-542, 2001
2312001
High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 96: 07
M Poulsen, D Rischin, E Walpole, J Harvey, J Mackintosh, J Ainslie, ...
Journal of Clinical Oncology 21 (23), 4371-4376, 2003
2272003
Phase II study of imatinib in patients with small cell lung cancer
BE Johnson, T Fischer, B Fischer, D Dunlop, D Rischin, S Silberman, ...
Clinical cancer research 9 (16), 5880-5887, 2003
2252003
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin
RW Tothill, A Kowalczyk, D Rischin, A Bousioutas, I Haviv, RK Van Laar, ...
Cancer Research 65 (10), 4031-4040, 2005
2172005
The system can't perform the operation now. Try again later.
Articles 1–20